5'-Heterogeneity of Glucocorticoid Receptor Messenger RNA Is Tissue Specific: Differential Regulation of Variant Transcripts by Early-Life Events
J. A. McCormick,
V. Lyons,
M. D. Jacobson,
J. Noble,
J. Diorio,
M. Nyirenda,
S. Weaver,
W. Ester,
J. L. W. Yau,
M. J. Meaney,
J. R. Seckl and
K. E. Chapman
Molecular Endocrinology (J.A.M., V.L., J.N., M.N., W.E., J.L.W.Y.,
J.R.S., K.E.C.) University of Edinburgh Molecular Medicine
Centre Western General Hospital Edinburgh, EH4 2XU, United
Kingdom
Millennium Pharmaceuticals, Inc. (M.D.J.)
Cambridge, Massachusetts 02139
Developmental
Neuroendocrinology Laboratory (S.W., M.J.M.) Douglas Research
Center Departments of Psychiatry, Neurology, and Neurosurgery
McGill University Montreal, H4H IR3, Canada
 |
ABSTRACT
|
---|
Glucocorticoid receptor (GR) gene expression is
regulated in a complex tissue-specific manner, notably by early-life
environmental events that program tissue GR levels. We have
identified and characterized several new rat GR mRNAs. All encode a
common protein, but differ in their 5'-leader sequences as a
consequence of alternate splicing of, potentially, 11 different exon 1
sequences. Most are located in a 3-kb CpG island, upstream of exon 2,
that exhibits substantial promoter activity in transfected cells.
Ribonuclease (RNase) protection analysis demonstrated significant
levels of six alternate exons 1 in vivo in rat, with
differences between liver, hippocampus, and thymus reflecting
tissue-specific differences in promoter activity. Two of the alternate
exons 1 (exons 16 and
110) were expressed in all tissues examined,
together present in 7787% of total GR mRNA. The remaining GR
transcripts contained tissue-specific alternate first exons.
Importantly, tissue-specific first exon usage was altered by perinatal
environmental manipulations. Postnatal handling, which permanently
increases GR in the hippocampus, causing attenuation of stress
responses, selectively elevated GR mRNA containing the
hippocampus-specific exon 17. Prenatal
glucocorticoid exposure, which increases hepatic GR expression and
produces adult hyperglycemia, decreased the proportion of hepatic GR
mRNA containing the predomin-ant exon 110,
suggesting an increase in a minor exon 1 variant. Such tissue
specificity of promoter usage allows differential GR regulation and
programming.
 |
INTRODUCTION
|
---|
Glucocorticoids maintain homeostasis after stress and
play key roles in differentiation, nervous system function,
and intermediary metabolism (1). The principal receptor for
glucocorticoids, the type II or glucocorticoid receptor (GR), a member
of the nuclear receptor family (reviewed in Ref. 2), is essential for
life ex utero (3). Although GRs are expressed in almost all
cells, the level of expression and receptor regulation vary
considerably between tissues, and even within a tissue
[e.g. hippocampus (4)]. The importance of maintaining an
appropriate level of expression of GR for the functional effects of
glucocorticoids has been demonstrated in vitro (5) and in
transgenic mice a reduction of 3050% in tissue levels of GR results
in major neuroendocrine, metabolic, and immunological abnormalities (6, 7). The level of expression of GR is thus critical for the correct
level of function of a cell. In some tissues, GRs are regulated by
glucocorticoids themselves, but again the regulation is highly tissue
specific, with GR down-regulated by glucocorticoids in some tissues,
but unaltered or even induced in others (8, 9, 10). This regulation occurs
chiefly at the level of transcription (9, 11). GR gene transcription
therefore must be tightly regulated with appropriately high expression
for the function of any particular cell.
Much evidence suggests that GR gene transcription is, in part,
permanently determined or programmed by perinatal events, again in a
cell-specific manner. Thus, animals exposed to short periods of
infantile stimulation (handling) have, as adults, permanently elevated
GR expression selectively in hippocampal neurons (12). The
hippocampus is a site of glucocorticoid feedback inhibition upon the
hypothalamic-pituitary-adrenal (HPA) axis, and adult rats handled as
neonates are therefore more sensitive to glucocorticoid-negative
feedback with decreased HPA responsivity to stress throughout life (12, 13). In contrast, prenatal treatment of rats with the synthetic
glucocorticoid dexamethasone permanently reduces GR mRNA in the
hippocampus (14), but increases GR mRNA in the liver (15). These
animals have permanently elevated levels of plasma corticosterone,
fasting hyperglycemia (attributable to elevated levels in liver of the
glucocorticoid-inducible enzyme, phosphoenolpyruvate carboxykinase, the
rate limiting step in gluconeogenesis), hyperinsulinemia (15), and
hypertension (14). A key question therefore, is how can GR mRNA levels
be regulated in a cell-specific and even opposite manner during adult
life and particularly by prenatal manipulations?
Surprisingly little is known of the mechanisms that control GR
gene transcription. The GR gene spans more than 80 kb and contains 8
coding exons (exons 2 to 9) (16, 17). The human (16, 18), mouse (17, 19), and rat (20) (M. D. Jacobson and K. R. Yamamoto,
unpublished data) GR gene promoter regions have been cloned and
partially characterized. A single promoter has been described for the
human GR gene (16, 18). In mouse, expression of the GR gene is
controlled by at least 3 promoters, resulting in GR transcripts with
different 5'-untranslated exons designated exons 1A (restricted to T
cell lines), 1B, and 1C (the latter is homologous to the exon 1 present
in the human GR cDNA) (17), and very recent evidence suggests the
existence of 2 more (21). It has been suggested that rat GR mRNA might
also exhibit 5'-heterogeneity (20). Little is known about GR promoter
usage in tissues in vivo. Here we demonstrate
tissue-specific 5'-heterogeneity of rat GR mRNA and present compelling
evidence for early-life environmental programming of specific GR gene
promoters in the hippocampus.
 |
RESULTS
|
---|
DNA Sequence of the Rat GR Gene Flanking the 5'-End of Exon 2
We have determined the sequence of 4600 bp of the rat GR gene
flanking the 5'- end of exon 2 (Fig. 1
).
The majority of this region corresponds to a CpG island (68% CG, with
a CG/GC ratio of
0.8 between -1620 and -4520 relative to the
translation start at +1, within exon 2) and contains the exon 1
sequence present in the published rat GR cDNA sequence (22) (-3269 to
-3322; here designated exon 16). The sequence is
highly conserved when compared with the mouse GR gene (19) (91%
identity throughout the whole region), including the mouse exons 1B and
1C (17). The rat sequence shows moderate conservation with the
corresponding human GR gene sequence (18, 23) (
70% identity over
the CpG island; nucleotides -1600 to -4220, but only 40% identity
over the region between -50 and -1600), including exon 1 present in
the human GR cDNA (24).

View larger version (76K):
[in this window]
[in a new window]
|
Figure 1. Sequence of 5'-DNA Flanking Exon 2 of the Rat GR
Gene
Numbering is with respect to the translation start, at +1.
Shaded regions indicate exon 1 sequences found in
5'-RACE clones amplified from hippocampal GR mRNA. In the case of exon
16 (which was not represented among the RACE clones) the
shaded nucleotides are those present in the cDNA
sequence (22 ). The start of exon 2 is at -13. GC boxes referred to in
the text are underlined; a putative NGFI-A site and a
sequence identical to a footprinted region in the human GR gene which
binds AP2 (referred to in the text) are boxed.
|
|
5'-RACE (Rapid Amplification of cDNA Ends)-PCR Identifies at Least
11 Alternative 5'-Leader Sequences in GR mRNA
To investigate 5'-heterogeneity in rat GR mRNA, we carried out
5'-RACE-PCR on total RNA isolated from rat hippocampus or thymus. Eight
separate 5'-RACE reactions were carried out on the products of 5
different dC-tailed cDNA reactions from hippocampal RNA; one 5'-RACE
reaction was carried out on dC-tailed cDNA produced from thymus RNA.
Subcloned products were sequenced with a primer complementary to exon 2
of GR. A total of 54 independent 5'-RACE products were obtained from
hippocampal RNA, deriving from independent cDNAs generated in the
initial reverse transcription reactions (the 5'-ends of the cDNAs
terminate at different positions in exon 1, indicating they are
unlikely to be generated by PCR from the same initial tailed cDNA). In
addition, four independent 5'-RACE products were obtained from thymus
RNA. The cDNA products fall into 10 classes based on the sequences
immediately upstream of exon 2 (Table 1
).
The majority of clones (31) from rat hippocampal GR mRNA contained exon
110 (corresponding to exon 1C of the mouse GR
gene and the exon 1 sequence present in the human GR cDNA sequence). In
addition, we found 7 novel exon 1 sequences present in rat hippocampal
GR mRNA, exons 13, 14,
15, 17,
18, 19, and
111 (Table 1
); exons 15 and
111 are likely to correspond to the recently
described mouse exons 1D and 1E (21), respectively. Of the minor exon 1
species, exons 17 and 111
represented the major variants, present in 8 (exon
17) and 5 (exon 111) of the
independent clones. Exons 14,
15, and 19 were present in,
respectively, 3, 2, and 3 of the independent 5'-RACE clones. Two of the
classes (13 and 18) were
represented each by a single independent clone. No clones were found
corresponding to the exon 1 sequence present in the published rat GR
cDNA sequence (22) (but see below). Of the 4 independent clones
produced from 5'-RACE PCR of thymus RNA, 2 contained exon
110. In addition, a further 2 novel variants of
rat GR mRNA were identified in thymus RNA, containing exons
11 and 12 (Table 1
). Exon
11 is likely to correspond to mouse exon 1A (76%
identity) (25), reportedly specific to T lymphocytes (17).
Sequence comparisons located 8 of the alternate
exons 1 to the CpG island upstream of exon 2 (Table 1
; summarized in
Fig. 2
). Each of the exons 1 that mapped
to this region was flanked, at the 3' end, by the conserved GT
dinucleotide splice donor site (Table 1
). Sequences corresponding to
exons 11, 12, and
13 were not found within the sequenced region,
and Southern blot hybridization showed they were not located within
208 (see Materials and Methods for details of
208),
indicating that they lie at least 15 kb 5' of exon 2 (data not
shown).

View larger version (9K):
[in this window]
[in a new window]
|
Figure 2. Relative Positions of Alternative Exons 1 of the
Rat GR Gene
Shown are the relative positions of exons 14,
15, 16, 17, 18,
19, 110, and 111, all located
within the CpG island 5' of exon 2. Exon 11 is located at
least 15 kb 5' of exon 2. Note, the size of exon 2 is not to scale.
|
|
Exon 110 Is Present in the Majority of GR
mRNA Transcripts in Hippocampus, Liver, and Thymus, but Some Other
Promoters Are Tissue Specific
To investigate the relative abundance of each of the variant GR
mRNA transcripts, RNase protection analysis was carried out with cRNA
probes generated using 5'-RACE clones as templates. Each probe was
complementary to a specific exon 1, and also to 186 nucleotides of exon
2 (common to all GR mRNA transcripts), thus giving 2 protected
products; a fragment of 186 nucleotides representing GR transcripts
containing exon 2 but lacking the target exon 1 sequence, and a larger
fragment complementary to transcripts containing both exons 1 and 2.
The sum of both fragments equates to total GR mRNA, allowing the amount
of exon 1-exon 2 containing mRNA to be calculated as a percentage of
total GR mRNA transcripts, after correction for differences in specific
activity. In hippocampus, liver, and thymus, as well as heart, kidney,
lung, and testis, transcripts containing exon 110
predominate (Fig. 3A
, Table 2
, and data not shown). Interestingly,
although exons 15 and 17
were both present in hippocampal GR mRNA (together accounting for
17% of GR mRNA in hippocampus), in liver and thymus they were below
the limit of detection of the RNase protection assay
(i.e. <1% of the total) (Table 2
). Furthermore, exon
111-containing transcripts were relatively more
abundant in hippocampus than in liver RNA but were below the limit of
detection of the assay in thymus (Table 2
). Exon
11, identified in a 5'-RACE clone from thymus,
was detectable only in thymus RNA by RNase protection analysis (Fig. 3B
and Table 2
). Exon 16 was not detected among the
products of 5'-RACE PCR on hippocampal RNA, possibly as a consequence
of the hybridization of the 5'-RACE UAP-anchor primer [which contains
a G(GGIIG)3 sequence] to a
C8 sequence close to the 3'-end of exon
16; 5'-RACE products likely to contain only very
short amounts of exon 1 sequence were not analyzed. However, exon
16 mRNA transcripts were expressed in all three
tissues, representing around 1020% of total GR mRNA (Table 2
).
Levels of exon 14-- and exon
12-containing GR mRNA were below the limit of
detection of the RNase protection assay (Table 2
).

View larger version (54K):
[in this window]
[in a new window]
|
Figure 3. RNase Protection Analysis of the Abundance of
Alternative Exon 1-Containing GR mRNAs in Rat Hippocampus, Liver, and
Thymus
RNase protection assays were carried out on 50 µg total RNA from
adult male rat hippocampus (H), liver (L), or thymus (T). Lanes marked
Y contained yeast RNA. Lanes marked + contained undigested probe; M,
markers. A, RNase protection of exon 110-containing GR
mRNA. Arrowheads indicate the positions of the
186-nucleotide fragment protected by GR mRNA transcripts containing
exon 2 but not exon 110 and the 306-nucleotide fragment
protected by transcripts containing exon 110 and exon 2.
The lane containing thymus RNA was from an adjacent gel run in parallel
under identical conditions. B, RNase protection of exon
11-containing GR mRNA. Arrowheads mark the
186-nucleotide fragment protected by GR mRNA transcripts containing
exon 2 but not exon 11 and the 228-nucleotide fragment
containing exon 11 and exon 2. Note that, for quantitation,
the 215-nucleotide band (which also contains exon 11
spliced to exon 2) was included.
|
|
Distribution of Alternate Exon 1-Containing GR mRNA Transcripts
within the Hippocampus
Using in situ mRNA hybridization, we mapped the
distribution of transcripts containing the major alternate first exons
of the GR gene expressed in the hippocampus. A similar sized cRNA probe
complementary to the 5'-end of the common exon 2 hybridized in a
pattern equivalent to that documented for GR mRNA in previous studies
(26) (Fig. 4A
). Using cRNA probes
specific to the major alternate first exons employed in the
hippocampus, we found that the predominant exon
110-containing transcript was distributed very
similarly to total GR mRNA, with high expression in the dentate gyrus
and CA1 and lower expression in CA3 and CA4 (Fig. 4E
). In contrast, GR
mRNA transcripts containing exons 15,
17, or 111 showed a more
homogeneous distribution, although in each case expression was highest
in the dentate gyrus and CA1 region of hippocampus (Fig. 4F
, C, and G,
respectively).

View larger version (110K):
[in this window]
[in a new window]
|
Figure 4. In Situ Hybridization Analysis of
the Distribution of GR mRNA within Hippocampus
In situ mRNA hybridization was carried out on rat
hippocampus using exon 1-specific cRNA probes. Distribution of GR mRNA
containing (A) exon 2 (total GR mRNA) and alternative exons 1 as
follows: (C) exon 17; (E) exon 110; (F) exon
15; and (G) exon 111. Representative sense
controls are shown in (B) exon 2 (sense control) and (D) exon
17 (sense control). Arrows indicate dentate
gyrus (DG), CA1, and CA3. Exposure times were 5 days (A, B, and G), 6
days (C, D, and E), and 12 days (F).
|
|
Promoter 17 Activity Is Highest in Central
Nervous System (CNS)-Derived Cells
To investigate whether the alternate exons 1 are associated with
promoter activity, regions of the rat GR gene were joined, within each
of the alternate exons 1, directly to a luciferase reporter gene (Fig. 5A
). Luciferase activity therefore arises
from chimeric RNA transcripts encoding part of an alternate exon 1 of
the GR gene at the 5'-end and represents the activity of the promoter
that directs transcription through that individual exon 1. Although
transcription may additionally originate from alternate
promoters present on the same genomic DNA fragment, these transcripts
will not be transcriptional fusions to luciferase and will not,
therefore, result in luciferase activity (there is no splice acceptor
site upstream of the luciferase gene in these constructs). To measure
promoter activity of the whole CpG island, including exons
14-111, plasmid P2 was
constructed in which the GR gene is joined to luciferase within exon 2
(just before the translation start) (Fig. 5A
). In P2, RNA initiating at
any of the transcription start sites will be spliced, from the donor
site at the 3'-end of the respective exon 1 onto the acceptor site at
the 5'-end of the common exon 2; luciferase reporter activity therefore
reflects the total promoter activity of the DNA fragment inserted into
P2.

View larger version (25K):
[in this window]
[in a new window]
|
Figure 5. Transfection Analysis of Promoter Activity
Associated with the Alternate Exons 1 of the Rat GR Gene
A, Diagrammatic representation of constructs used in transfection
analysis. Restriction fragments containing regions of the rat GR gene
were fused, within specific exons, to the luciferase reporter gene in a
modified pGL3-Basic vector. P2(rev) contains the identical fragment to
P2, in the reverse orientation with respect to luciferase.
indicates the splice acceptor site in the intron 5' of exon 2. B,
Promoter activity of regions of the GR gene in three cell lines, HepG2
hepatoma cells, C6 glioma cells, and B103 neuroblastoma cells. Activity
of P2 (spanning the whole CpG island, fused to luciferase within exon
2) was nominally set to 100% for each cell line, and activity of the
other constructs was expressed relative to this value. Values represent
means ± SEM.
|
|
Promoter activity was assayed in transiently transfected HepG2 (human
hepatoma), C6 (rat glioma), and B103 (rat neuroblastoma) cells. P2 had
the highest promoter activity in all three cell lines examined, whereas
the same fragment in the reverse orientation with respect to luciferase
had no significant activity (Fig. 5B
). Activity of all constructs was
similar in all three cell lines with the exception of
P17. P17 was, apart from
P2, the most active construct in B103 and C6 cells but was relatively
less active in HepG2 cells (Fig. 5B
). Promoter activity of
P110 was high and P111
activity low in all three cell lines (Fig. 5B
).
Differential Regulation of Variant GR mRNA Transcripts by
Early-Life Events
Neonatal handling causes marked and permanent increases in GR mRNA
expression in hippocampus (27). Strikingly, neonatal handling induced
expression of GR mRNA containing the hippocampus-specific exon
17 by 2.5- to 3-fold selectively across all
hippocampal subfields (Fig. 6A
), whereas
expression of exon 17-containing GR mRNA in
cortex, where neonatal handling has no effect on expression of GR, was
unchanged by the manipulation (Fig. 6A
). In contrast, the level of
expression and distribution of the major exon
110, and the other hippocampus-specific exons
15- and 111-containing GR
mRNAs were unaffected by neonatal handling (Fig. 6B
and data not
shown). To start to examine whether this effect was confined to the
hippocampus, we examined rats exposed prenatally to dexamethasone
(dexamethasone administered during week 3 of gestation). This
manipulation selectively and permanently increases hepatic GR mRNA
levels by 25% (15). In these animals RNase protection assays show a
significant decrease in the relative amount of exon
110-containing GR mRNA in the liver in the
dexamethasone-treated group (73 ± 3%; n = 10) compared with
controls (82 ± 2%; n = 9, P < 0.05) (an
increase in one of the minor GR mRNA species would reduce the level of
exon 110-containing RNA as a percentage of the
total). These data suggest that prenatal dexamethasone treatment
induces one of the minor mRNA variants. However, RNase protection
assays demonstrated that the level of exon
16-containing GR mRNA was unchanged in livers
from adult rats treated with dexamethasone prenatally (9 ± 1%;
n = 4), compared with controls (9 ± 1%; n = 5). Exon
11, 15,
17, and 111-containing GR
mRNAs remained very low or were undetectable, suggesting that an as yet
unidentified exon 1-containing GR mRNA is induced in these animals.

View larger version (30K):
[in this window]
[in a new window]
|
Figure 6. Exon 17-containing GR mRNA Is Induced
in Hippocampus by Neonatal Handling
In situ mRNA hybridization analysis of GR mRNA
containing exon 17 (A) or exon 110 (B) within
the dentate gyrus (DG), the CA1 and CA3 pyramidal cell fields of the
hippocampus and the cortex (CTX). Expression was measured in handled
animals (hatched columns) and nonhandled animals
(black columns) and is expressed as the number of grains
over an area equivalent to a CA1 neuron. Values represent mean ±
SEM; n = 5. *, P < 0.05.
|
|
 |
DISCUSSION
|
---|
The organization of the 5'-end of the rat GR gene is complex. Here
we show the gene encodes at least 11 alternate first exons, some of
which are tissue-specific, and one of which is differentially and
permanently induced by early-life manipulation. None of the alternate
exons 1 is predicted to alter the amino acid sequence of the GR itself;
there is an in-frame stop codon present immediately 5' to the
translation initiation site in exon 2, common to all the mRNA variants.
Of the 10 alternate exons 1 we identified by 5'-RACE, 4 correspond to
alternative exons 1 previously identified in mouse, exons
11, 15,
19, and 110 (17, 21). Rat
exon 11 lies at least 15 kb upstream of exon 2
(it is not present on
208 containing 15 kb of DNA 5' of exon 2) and
is probably in a similar position to the corresponding mouse exon. All
the other alternate exons 1 identified here are novel. Sequence
analysis of DNA flanking the 5'-end of exon 2 revealed that most of the
novel exons 1 lie within a CpG island highly conserved between rat and
mouse. The 3-kb CG-rich region, therefore, contains at least 8
alternate exons 1 (including exon 16, present in
the published rat GR cDNA sequence), at least 5 of which are conserved
in the mouse. The CpG island is also conserved in the human GR gene,
indicating that the use of alternate exons 1 in GR gene expression may
also occur in humans.
At least 6 of the alternate exons 1 are present in vivo in
rat GR mRNA. In all adult rat tissues examined, GR mRNA containing exon
110 predominated, accounting for at least half of
total GR transcripts. Exon 16 was also present
ubiquitously, in a substantial minority of total GR mRNA. All other
alternate exons 1 were, to varying extents, expressed in a
tissue-specific manner. Exon 11 was well
represented in GR mRNA in thymus, but was absent from hippocampus and
liver. Preliminary data suggest that exon 11 is
not restricted to a specific subset of cells in thymus, but is
expressed similarly in thymocytes and thymic epithelium (A. Dammermann,
C. Blackburn, and K.E. Chapman, unpublished observations). Hippocampal
RNA contained significant levels of the minor exon
15-, 17-, and
111-containing GR mRNA variants that were
expressed at either low or undetectable levels in liver and thymus.
Five other exon 1 variants (12,
13, 14,
18, and 19) are unlikely to
be of significance as they were poorly represented in the 5'-RACE PCR
or were undetectable by RNase protection assays. It is unlikely that
any further GR mRNA variants are present at significant levels in
hippocampus as the sum of the exon 1 variants examined was close to
100% of total mRNA. Interestingly, exon 110-,
16-, and 111-containing
transcripts accounted for only 90% of the GR mRNA in liver, suggesting
that additional novel exon 1 sequences may be present.
In transient transfection experiments, a construct encoding the whole
CpG island of the GR gene, including 8 of the alternate exons 1 and the
splice acceptor site within the intron 5' of exon 2, fused to a
luciferase reporter gene within exon 2 (P2), exhibited substantial
promoter activity in all cell lines tested. This activity results from
transcripts originating at any point within the CpG island that are
spliced from an appropriate donor site onto the splice acceptor site 5'
to exon 2, and represents the sum of the activity of individual
promoters on the genomic DNA fragment. Promoter activity was also
associated with particular regions of the CpG island, where the fusion
to luciferase was made within specific exon 1 sequences. In these
cases, no splice acceptor site is available within the luciferase gene,
and a transcriptional fusion is generated between the specific exon 1
and the luciferase reporter; luciferase activity therefore reflects
transcription through the specific exon 1. Relative activity of these
constructs in different cell types was similar with one notable
exception, P17 (see below). The low activity of
P111, compared with the shorter constructs or to
P2, probably results from promoter competition by the stronger
promoters directing transcription of exon 16 and
exon 110, neither of which will generate
productive RNA transcripts encoding luciferase, due to the lack of a
splice acceptor site. Interestingly, P17, fused
to luciferase within exon 17, had the highest
activity of any single promoter construct (P2 activity reflecting
activity of the whole region) in B103 and C6 cells, both CNS derived.
The activity of this construct was low in hepatic cells, in which
P16 and P110 had the
highest activity. In vivo, GR mRNA transcripts containing
exon 17 were present at significant levels in
hippocampus, but absent from liver, suggesting that factors present in
cells of CNS origin are responsible for transcription initiation at the
promoter upstream of exon 17 in rat
hippocampus.
Neonatal handling induces an increase of approximately 50% in total GR
mRNA levels in all subfields of the hippocampus, but not in cortex
(27). Only the 17 variant GR mRNA was induced in
the hippocampus by handling, with a 2- to 3-fold increase, also across
all fields of the hippocampus. RNase protection assays, carried out on
RNA extracted from the whole hippocampus (which will include glia and
interneurons, as well as pyramidal cells and the granule cells of the
dentate gyrus) showed that exon 17-containing GR
mRNA is normally present in approximately 10% of total GR mRNA in
hippocampus. The observed induction of 17 may not
appear sufficient to account for the overall increase of approximately
50% in steady state GR mRNA levels after handling (27). However, the
heterogeneity of the hippocampus as a whole may have resulted in a
dilution of exon 17-containing GR mRNA if it is
expressed predominantly in the pyramidal cell layers of the hippocampus
and granule cells of the dentate gyrus, thereby lowering the estimate
of the amount of exon 17-containing GR mRNA
present in these hippocampal neuronal layers obtained by RNase
protection assays of whole hippocampus. Indeed, we have previously
noted a similar discrepancy between the magnitude of change in mRNA
encoding the type I inositol 1,4,5-triphosphate receptor during human
pregnancy measured by RNase protection assays and in situ
mRNA hybridization (28). Although we cannot exclude the possibility
that an additional minor variant of GR mRNA is induced by neonatal
handling, none of the other main variant GR transcripts were altered by
handling. These data suggest that neonatal handling programs increased
hippocampal GR via increased transcription from a novel promoter,
17, active predominantly in CNS-derived cells. A
similar permanent induction of a minor promoter of the GR gene appears
likely in the liver after prenatal dexamethasone exposure. Within the
overall increase in GR mRNA in liver of prenatally treated rats, the
proportion containing the predominant exon 110
fell, although we were unable to identify a specific transcript
induced. Nevertheless, the clear implication is that early life
programming events selectively alter otherwise minor tissue-specific GR
gene transcripts, whereas the major and ubiquitous promoters are
unaffected, thus programming GR levels for the lifetime of the animal
in a tissue-specific manner. Conversely, it is possible that
manipulations that decrease GR levels may decrease the levels of the
minor GR mRNA variants.
5HT appears crucial in mediating the effects of neonatal handling upon
GR expression in hippocampus (29, 30), with subsequent effects upon HPA
axis activity (31, 32). The transcription factors NGFI-A and AP2 have
been implicated in the induction of GR in the hippocampus after
handling or with 5HT (33). Intriguingly, a sequence in the human GR
gene that binds AP2 in vitro (34) is completely conserved in
the rat GR gene (at -2718). Additionally, within the CpG island, the
GR gene contains 16 GC boxes (GGGCGG), which form the core consensus
Sp1 site (35) and which may also bind NGFI-A; indeed, there is a
sequence exactly matching the consensus binding site for the family of
zinc finger proteins that includes NGFI-A (36) immediately upstream of
exon 17. We speculate that the increases in AP2
and NGFI-A induced by neonatal handling cause increased transcription
from a promoter adjacent to exon 17, leading to
increased total GR mRNA.
It remains possible that transcription may originate at a common
promoter further upstream, resulting in a common exon 0, which is then
spliced upstream of the alternate exons 1. We consider this to be
extremely unlikely for the following reasons. First, sequence analysis
of 58 independent 5'-RACE clones neither provided evidence for a common
5'-leader sequence nor revealed any lack of colinearity with the
genomic sequence. Second, the predominant rat exon
110 is homologous to exon 1 of the human GR gene
(16, 18) for which a transcription start site has been mapped. A number
of transcription start sites exist (typically for a TATA-less CG-rich
promoter), but all are located within the region corresponding to rat
exon 110, and all appear to extend to the same
3'-splice site (16, 18). Similarly, sequencing of our 5'-RACE clones
and RNase protection analysis (to map transcription start sites)
suggests that a number of transcription starts exist at least for exon
110 and probably for other exons 1 also (J.
A. McCormick, V. Lyons, and K. E. Chapman, unpublished
observations). Indeed, the 5'-end of the longest of our 5'-RACE clones
containing exon 110 corresponds exactly to one of
the transcription starts mapped for human GR mRNA (18) (Fig. 1
).
Finally, our transfection data suggest that promoter activity is
associated with the 5'-flanking regions of specific exons 1. Thus, it
is most probable that alternate exon 1 usage results from transcription
initiation at a number of predominant transcription start sites within
the CpG island, associated with promoter activity. CpG islands are
frequently associated with multiple transcription initiation sites,
often spread over a distance of up to 1 kb, resulting in transcripts
with differing exons 1, all of which, however, are spliced at the same
3'-splice donor site onto exon 2 (e.g. Refs. 37, 38).
Multiple 5'-ends are not usually associated with alternate splice donor
sites, giving rise to discrete alternate exons 1, as we have observed
for the rat GR gene. It is possible that, as the CpG island in the GR
gene is very large, transcription initiates at a large number of
initiation sites spread over the entire 3-kb region. The probability of
splice donor sites occurring within such a large region is high, and
the splicing machinery associated with the RNA polymerase complex may
simply splice from the first appropriate splice donor site that occurs
to the splice acceptor site before exon 2. This hypothesis is supported
by the sequence of mouse exon 1E (corresponding to exon
111) which, at the 5'-end, includes a portion of
exon 1C (corresponding to exon 110) as well as
the intervening genomic DNA (21). Possibly, transcription originated
too far 3' within exon 110 to utilize the exon
110 splice donor site; splicing then occurred at
the next available splice donor site, 3' of exon
111. Certain sites within the CpG island will be
favored for transcription initiation, and this will probably vary in a
tissue-specific manner. Indeed, we see the highest number of variant
exons 1 in hippocampus, a tissue exhibiting a high degree of
complexity. This hypothesis predicts that more alternative exons 1 may
exist in the CpG island if more splice donor sites are predicted, and
we have preliminary evidence that this is the case (V. Lyons and
K. E. Chapman, unpublished observations).
The use of multiple and tissue-specific promoters provides a flexible
mechanism for distinct tissue-specific regulation of individual
promoters by hormonal signals and has been described for other members
of the steroid receptor family (39, 40, 41). GRs are widely expressed in
virtually all cell types, although expression levels and functions vary
considerably. The complex organization of the 5'-end of the GR gene may
reflect this need for diverse tissue-specific regulation. We speculate
that exon 110 is constitutively expressed in all
tissues, providing a basal or minimal constitutive level of GR gene
transcription (e.g. Ref. 8). The existence of
tissue-specific promoters (e.g. 11 in
thymus and 17 in hippocampus) permits
differential regulation of GR in specific cell types and may explain
the opposite regulatory effects of glucocorticoid hormones on the
levels of GR in T lymphocytes and hippocampus (10, 42). In addition,
the presence of several minor promoters clustered together may permit
regulation of one or more by signal transduction pathways, resulting in
moderate, but biologically significant, changes in total GR mRNA in a
specific cell type and thus, ultimately, the glucocorticoid signal on
the target genes. Our data illustrate the complexity of transcriptional
regulation of GR and provide a basis to understand tissue-specific
effects of early-life programming.
 |
MATERIALS AND METHODS
|
---|
Experimental Animals
Animals were maintained under controlled lighting (lights on
0700 to 1900 h) and temperature (22 C) with water and food
available ad libitum. Tissues for RNA isolation and in
situ hybridization were from adult (38 months) male Wistar rats
(Charles River UK Ltd, Margate, Kent, UK). Animals treated
in utero with dexamethasone were male offspring (8 months
old) of female Wistar rats administered dexamethasone (100 µg/kg per
day) during week 3 of pregnancy, as previously described (15). For
neonatal handling, Long-Evans rats (Charles River Canada, St. Constant,
Québec, Canada) were used as previously described (30). Handling
was carried out daily for 2 weeks. Male animals were selected at random
from a total of five litters and were used when they reached adult
age (35 months).
All studies involving animals described herein were approved of by the
UK Home Office and were performed in strict accordance with the UK Home
Office Animals (Scientific Procedures) Act, 1986.
Isolation of RNA
Total RNA was isolated using the guanidinium isothiocyanate
method (43). Integrity was verified by electrophoresis on
formaldehyde-agarose gels.
5'-RACE PCR
5'-RACE PCR was performed using a commercial kit (Life Technologies , Gaithersburg, MD) according to the
manufacturers instructions. First-strand synthesis of GR cDNA was
carried out at 42 C for 30 min on 5 µg total RNA using 8 U/µl
SuperScript II RT and 100 nM primer GSP1
(5'-AAGGGATGCTGTATTCA-3') in a 25 µl reaction containing 20
mM Tris HCl (pH 8.4), 50 mM KCl, 3
mM MgCl2, 10 mM
dithiothreitol, 400 µM deoxynucleoside
triphosphates (dNTPs). After RNase H treatment, cDNA was added to a 24
µl reaction containing 20 mM Tris HCl (pH 8.4), 50
mM KCl, 1.5 mM MgCl2, 200
µM dCTP, and 0.4 U/µl terminal deoxynucleotidyl
transferase. dC-tailed cDNA (5 µl) was used in a PCR reaction with
400 nM anchor primer
(5'-CUACUACUACUAGGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3'), 440
nM primer GSP2 (5'-ACTCCAAATCCTTCAAGAGGTCA-3'), 20
mM Tris HCl (pH 8.4), 50 mM KCl, 1.5
mM MgCl2, 200 µM dNTPs,
and 2.5 U Taq DNA polymerase (Promega Corp.,
Madison, WI), with 35 cycles of PCR amplification (96 C, 45 sec; 45 C,
40 sec; 72 C, 1.5 min), followed by 10 min, 72 C. A nested PCR was
carried out on the products of the first PCR reaction, under the same
conditions with the following primers: UAP
(5'-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3') and GSP3
(5'-TTGGAATCT-GCCTGAGAAGC-3'). PCR products were cloned into pGEM-T or
pGEM-T-easy (Promega Corp.) and sequenced using GSP3.
Subcloning and Sequence Analysis of the Rat GR Promoter
208 contains exon 2 and approximately 15 kb of the rat GR
gene flanking the 5'-end of exon 2 (M. D. Jacobson, unpublished
data). The sequence between -4600 and +500 (the translation start
close to the 5'-end of exon 2 is designated +1) was determined from
restriction fragments subcloned from
208 on both strands using the
Sequenase II system (Amersham International,
Buckinghamshire, UK) or the Thermo Sequenase
33P-radiolabeled terminator cycle sequencing
system (Amersham International). Sequence analysis,
including identification of putative transcription factor-binding sites
was carried out using computer software available at the UK MRC Human
Genome Mapping Project Resource Centre.
Accession Number
The nucleotide sequence data reported in this paper will appear
in the EMBL, GenBank, and DDBJ Nucleotide Sequence Databases under
the accession number AJ271870.
Transfection Analysis Of GR Promoter Activity
Plasmids that fused the rat GR gene to a luciferase reporter
gene were constructed from appropriate restriction fragments ligated
into pGL3-Basic (Promega Corp.) containing a modified
polylinker as follows: P2, a HindIII/SspI
fragment encoding rat GR from -4572 to -9 (the ATG translation start
is designated +1); P2(rev), the same fragment in the reverse
orientation with respect to luciferase; P16, a
HindIII/PstI fragment encoding -4572 to -3336;
P17, a HindIII/BglI
fragment encoding -4572 to -2931; P110, a
HindIII/HincII fragment encoding -4572 to
-2318, and P111, a
HindIII/PstI fragment encoding -4572 to -1767.
Plasmid DNAs used for transfections were purified by CsCl density
gradient centrifugation.
HepG2 (human hepatoma), C6 (rat glioma), and B103 (rat neuroblastoma)
cells were maintained in DMEM supplemented with 10% (vol/vol) FBS, 100
IU/ml penicillin, and 100 µg/ml streptomycin. Twenty four hours prior
to transfection, HepG2 and C6 cells were seeded at 57 x
105 cells per 60-mm dish and B103 cells at 2
x 105 cells per 60-mm dish. Cells were
transfected using the calcium phosphate procedure (44) with 1 µg
modified pGL3-Basic or an equimolar amount of GR promoter-luciferase
plasmid (plasmids varied markedly in size), 1 µg of the
ß-galactosidase expression plasmid pCH110 (Pharmacia Biotech, Piscataway, NJ), and carrier pGEM-3 (Promega Corp.) to a total of 10 µg. Forty eight hours after
transfection, cells were lysed and luciferase activity determined as
previously described (44). ß-Galactosidase activity was determined
using the Tropix Galacto-Light kit (Cambridge Bioscience, Cambridge,
UK), and luciferase activity/ß-galactosidase activity was calculated.
Transfections were carried out in triplicate; each experiment was
repeated at least twice and two independently prepared plasmid DNAs
were used for each promoter construct.
RNase Protection Assays
With the exception of exon 16 (see below),
exon 1-specific cRNA probes were synthesized from corresponding 5'-RACE
subclones, linearized, and transcribed with either T7 or SP6 phage
polymerase, as appropriate, in the presence of either
[
-32P]-UTP or
[
-32P]-GTP (3000 Ci/mmol; Amersham International). The template used to synthesize an exon
16-specific cRNA probe was made by subcloning
into pGEM-T-easy an RT-PCR product generated from total rat liver RNA
using GSP3 (complementary to exon 2) and 5'-primer (5'-ACC-
TGGCGGCACGCGA-3').
RNase protection assays were carried out using a HybSpeed RPA kit
(Ambion, Inc., Austin, TX). Hybridization conditions were
optimized in preliminary experiments using synthetic RNA templates.
Total RNA (50 µg) was coprecipitated with 510 x
105 cpm cRNA probe, resuspended in 20 µl
hybridization buffer (supplied with the kit) at 95 C, and incubated at
68 C for 1 h. Reactions were incubated with RNase
A/T1 (1:25 dilution) for 30 min, 37 C, and RNA
products were separated on a 4% polyacrylamide gel containing 7
M urea and visualized using autoradiography or a
PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA).
Data were analyzed using Students t test. Significance was
set at P < 0.05.
In Situ mRNA Hybridizations
[35S]UTP-labeled RNA probes were
synthesized as previously described (26). After DNase I treatment,
unincorporated nucleotides were removed by passage over a Sephadex G-50
Nick column (Pharmacia Biotech, St Albans, UK). Exon
15-, 17-,
111-, and exon 2-specific templates were
generated by PCR carried out on subclones of
208 using the following
oligonucleotides tagged with sequences encoding either a T3 promoter
(to make sense RNA) or a T7 promoter (to make cRNA or antisense RNA):
15, 5'-primer
(5'-TATTAACCCTCACTAAAGGGTAAGAGGAGGGCGGACT-3'), 3'-primer
(5'-TTAAT-ACGACTCACTATAGGGCCAGCGCGCTCACACT-3');
17, 5'-primer
(5'-CATTAACC-CTCACTAAAGGGC-ACCGTTTCCGTGCAT-3'),
3'-primer (5'-TTAATACGACT-CAC-TATAGGGCAGCGTGTGCCGACCT-3');
111, 5'-primer
(5'-TATTAACCCTCACTAAA-GGGAGCGGCGTCTGGACC-3'), 3'-primer
(5'-TTAATACGACTCACTATAGGGCTA-GCGCTCAAGTTGTC-3') and exon 2, 5'-primer
(5'-ATTAACCCTCACTAAAGGGCC-AATGGACTCCAAAGAA-3') and 3'-primer
(5'-ATAATACGACTCACTATAGGGAA-TCTGCCTGAGAAGC-3'). The template used to
synthesize exon 110-specific cRNA was generated
by PCR from an exon 110 5'-RACE clone using UAP
and 3'-primer (5'-ATAATACGACTCACTATAGGGCTTTGGAGTCCA-
TTGGCA-3').
In situ-hybridization histochemistry was carried out as previously
described (26, 45). Silver grains were counted under bright-field
illumination using an image analysis system (MCID, Research Imaging,
St. Catherines, Ontario, Canada). Results were analyzed blind and
background, counted over adjacent areas of neuropil, was subtracted.
Data were analyzed using Students t test. Significance was
set at P < 0.05.
 |
ACKNOWLEDGMENTS
|
---|
We are very grateful to Professor K. R. Yamamoto for
providing materials, information, and helpful advice on this work, and
to Professor D. Schubert for B103 cells. We thank members of the
Molecular Endocrinology group and Drs. C. J. Kenyon, B. R.
Walker, and M. C. Holmes, in particular, for many discussions on
this work and for helpful comments on the manuscript.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Karen E. Chapman, Molecular Endocrinology, University of Edinburgh, Molecular Medicine Centre, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
This work was supported by a Wellcome Trust programme grant and Senior
Clinical Research Fellowship (J.R.S). J.A.M. is supported by a
studentship from the Medical Research Council.
Received for publication September 14, 1999.
Revision received November 29, 1999.
Accepted for publication January 5, 2000.
 |
REFERENCES
|
---|
-
Felig P, Baxter JD, Frohman LA 1995 Endocrinology and
Metabolism. McGraw-Hill, Inc, New York
-
Beato M, Herrlich P, Schütz G 1995 Steroid
hormone receptors: many actors in search of a plot. Cell 83:851857[Medline]
-
Cole T, Blendy JA, Monaghan AP, Kriegelstein K, Schmid W,
Fantuzzi G, Hummler E, Unsicker K, Schütz G 1995 Targeted
disruption of the glucocorticoid receptor blocks adrenergic chromaffin
cell development and severely retards lung maturation. Genes Dev 9:16081621[Abstract]
-
Herman JP, Patel PD, Akil H, Watson SJ 1989 Localization and
regulation of glucocorticoid and mineralocorticoid receptor messenger
RNAs in the hippocampal formation of the rat. Mol Endocrinol 3:18861894[Abstract]
-
Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR 1987 Intracellular receptor concentration limits glucocorticoid-dependent
enhancer activity. Mol Endocrinol 1:6874[Abstract]
-
Pepin M-C, Pothier F, Barden N 1992 Impaired type II
glucocorticoid receptor function in mice bearing antisense RNA
transgene. Nature 355:725728[CrossRef][Medline]
-
King LB, Vacchio MS, Dixon K, Hunziker R, Margulies DH,
Ashwell JD 1995 A targeted glucocorticoid receptor antisense transgene
increases thymocyte apoptosis and alters thymocyte development.
Immunity 3:647656[Medline]
-
Kalinyak JE, Dorin RI, Hoffman AR, Perlman AJ 1987 Tissue-specific regulation of glucocorticoid receptor mRNA by
dexamethasone. J Biol Chem 262:1044110444[Abstract/Free Full Text]
-
Rosewicz S, McDonald AR, Maddux BA, Goldfine ID, Miesfeld RL,
Logsdon CD 1988 Mechanism of glucocorticoid receptor down-regulation by
glucocorticoids. J Biol Chem 263:25812584[Abstract/Free Full Text]
-
Eisen, LP, Elsasser MS, Harmon JM 1988 Positive regulation of
the glucocorticoid receptor in human T-cells sensitive to the cytolytic
effects of glucocorticoids. J Biol Chem 263:1204412048[Abstract/Free Full Text]
-
Dong, Y, Poellinger L, Gustafsson J-Å, Okret S 1988 Regulation of glucocorticoid receptor expression: evidence for
transcriptional and posttranslational mechanisms. Mol Endocrinol 2:12561264[Abstract]
-
Francis D, Diorio J, LaPlante P, Weaver S, Seckl JR, Meaney MJ 1996 The role of early environmental events in regulating
neuroendocrine development. Ann NY Acad Sci 794:136152[Medline]
-
Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman
A, Sharma S, Pearson D, Plotsky PM, Meaney MJ 1997 Maternal care,
hippocampal glucocorticoid receptors, and
hypothalamic-pituitary-adrenal responses to stress. Science 277:16591662[Abstract/Free Full Text]
-
Levitt NS, Lindsay RS, Holmes MC, Seckl JR 1996 Dexamethasone
in the last week of pregnancy attenuates hippocampal glucocorticoid
receptor gene expression and elevates blood pressure in the adult
offspring in the rat. Neuroendocrinology 64:412418[Medline]
-
Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR 1998 Glucocorticoid exposure in late gestation permanently programs rat
hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor
expression and causes glucose intolerance in adult offspring. J
Clin Invest 101:21742181[Abstract/Free Full Text]
-
Encio IJ, Detera-Wadleigh SD 1991 The genomic structure of the
human glucocorticoid receptor. J Biol Chem 266:71827188[Abstract/Free Full Text]
-
Strähle U, Schmidt A, Kelsey G, Stewart AF, Cole TJ,
Schmid W, Schütz G 1992 At least three promoters direct
expression of the mouse glucocorticoid receptor gene. Proc Natl Acad
Sci USA 89:67316735[Abstract]
-
Zong J, Ashraf J, Thompson EB 1990 The promoter and first,
untranslated exon of the human glucocorticoid receptor gene are GC rich
but lack consensus glucocorticoid receptor element sites. Mol Cell Biol 10:55805585[Medline]
-
Cole, TJ 1992 M. Musculus gene for glucocorticoid receptor.
Genbank accession number: X66367
-
Gearing KL, Cairns W, Okret S, Gustafsson J-Å 1993 Heterogeneity in the 5' untranslated region of the rat glucocorticoid
receptor mRNA. J Steroid Biochem Mol Biol 46:635639[CrossRef][Medline]
-
Chen FH, Watson CS, Gametchu B 1999 Multiple glucocorticoid
receptor transcripts in membrane glucocorticoid receptor-enriched S-49
mouse lymphoma cells. J Cell Biochem 74:418429[CrossRef][Medline]
-
Miesfeld R, Rusconi S, Godowski PJ, Maler BA, Okret S,
Wikström AC, Gustafsson J-Å, Yamamoto KR 1986 Genetic
complementation of a glucocorticoid receptor deficiency by expression
of cloned receptor cDNA. Cell 46:389399[Medline]
-
Govindan MV, Pothier F, Leclerc S, Palaniswami R, Xie B 1991 Human glucocorticoid receptor gene promoter: homologous down
regulation. J Steroid Biochem Mol Biol 40:317323[CrossRef][Medline]
-
Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R,
Thompson EB, Rosenfeld MG, Evans RM 1985 Primary structure and
expression of a functional human glucocorticoid receptor cDNA. Nature 318:635641[Medline]
-
Chen FH, Watson CS, Gametchu B 1999 Association of the
glucocorticoid receptor alternatively-spliced transcript 1A with the
presence of the high molecular weight membrane glucocorticoid receptor
in mouse lymphoma cells. J Cell Biochem 74:430446[CrossRef][Medline]
-
Seckl JR, Dickson KL, Fink G 1990 Central
5,7-dihydroxytryptamine lesions decrease hippocampal glucocorticoid and
mineralocorticoid receptor messenger ribonucleic acid expression.
J Neuroendocrinol 2:911916
-
ODonnell D, La Roque S, Seckl JR, Meaney M 1994 Postnatal
handling alters glucocorticoid but not mineralocorticoid receptor mRNA
expression in the hippocampus of adult rats. Mol Brain Res 26:242248[Medline]
-
Martin C, Chapman KE, Thornton S, Ashley RH 1999 Changes in
the expression of myometrial ryanodine receptor mRNAs during human
pregnancy. Biochim Biophys Acta 1451:343352[CrossRef][Medline]
-
Mitchell JB, Iny LJ, Meaney MJ 1990 The role of serotonin in
the development and environmental regulation of type II corticosteroid
receptor binding in rat hippocampus. Dev Brain Res 55:231235[Medline]
-
Smythe JW, Rowe WB, Meaney MJ 1994 Neonatal handling alters
serotonin (5-HT) turnover and 5-HT2 receptor binding in selected brain
regions: relationship to the handling effect on glucocorticoid receptor
expression. Dev Brain Res 80:183189[Medline]
-
Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM 1988 Effect of neonatal handling on age-related impairments associated
with the hippocampus. Science 239:766768[Medline]
-
Meaney MJ, Aitken DH, Viau V, Sharma S, Sarrieau A 1989 Neonatal handling alters adrenocortical negative feedback sensitivity
and hippocampal type II glucocorticoid receptor binding in the rat.
Neuroendocrinology 50:597604[Medline]
-
Meaney MJ, Diorio J, Francis D, Yau J, Chapman K, Seckl JR
Early infantile stimulation (postnatal handling) increases the
expression of cAMP-inducible transcription factors in the rat
hippocampus: the effects of thyroid hormones, serotonin. J
Neurosci, in press
-
Nobukuni Y, Smith CL, Hager GL, Detera-Wadleigh SD 1995 Characterization of the human glucocorticoid receptor promoter.
Biochemistry 34:82078214[Medline]
-
Kadonaga JT, Jones KA, Tjian R 1986 Promoter-specific
activation of RNA polymerase II transcription by Sp1. Trends Biochem
Sci 11:2023[CrossRef]
-
Crosby SD, Puetz JJ, Simburger KS, Fahrner TJ, Milbrandt J 1991 The early response gene NGFI-C encodes a zinc finger
transcriptional activator and is a member of the GCGGGGGCG (GSG)
element-binding protein family. Mol Cell Biol 11:38353841[Medline]
-
Koller E, Hayman AR, Trueb B 1991 The promoter of the chicken
a2(VI) collagen gene has features characteristic of house-keeping genes
and of protooncogenes. Nucleic Acids Res 19:485491[Abstract]
-
Ye K, Dinarello CA, Clark BD 1993 Identification of the
promoter region of human Interleukin-1 type 1 receptor gene: multiple
initiation sites, high G+C content, and constitutive expression. Proc
Natl Acad Sci USA 90:22952299[Abstract]
-
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer
H, Chambon P 1990 2 Distinct estrogen-regulated promoters generate
transcripts encoding the 2 functionally different human progesterone
receptor form A and form B. EMBO J 9:16031614[Abstract]
-
Kwak SP, Patel PD, Thompson RC, Akil H, Watson SJ 1993 5'-Heterogeneity of the mineralocorticoid receptor messenger
ribonucleic acid: differential expression and regulation of splice
variants within the rat hippocampus. Endocrinology 133:23442350[Abstract]
-
Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F 1998 Differentially expressed messenger RNA isoforms of the human
estrogen receptor-
gene are generated by alternative splicing
and promoter usage. Mol Endocrinol 12:19391954[Abstract/Free Full Text]
-
Sapolsky RM, Krey LC, McEwen BS 1984 Stress down-regulates
corticosterone receptors in a site-specific manner in the brain.
Endocrinology 114:287292[Abstract]
-
Chomczynski P, Sacchi N 1987 Single-step method of RNA
isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal
Biochem 162:156159[CrossRef][Medline]
-
Voice MW, Seckl JR, Edwards CRW, Chapman KE 1996 11ß-hydroxysteroid dehydrogenase type 1 expression in 2S-FAZA
hepatoma cells is hormonally regulated; a model system for the study of
hepatic glucocorticoid metabolism. Biochem J 317:621625[Medline]
-
Yau JLW, Noble J, Widdowson J, Seckl JR 1997 Impact of
adrenalectomy on 5-HT6 and 5-HT7 receptor gene expression in the rat
hippocampus. Mol Brain Res 45:182186[Medline]